Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.
Thrombocytosis at diagnosis is uncommon in myelodysplastic (MDS) and myelodysplastic/myeloproliferative (MDS/MPD) syndromes. We conducted a retrospective analysis to determine the clinical and haematopathological features of such patients, and the effect of thrombocytosis on prognosis. Of the 388 patients diagnosed with MDS from 1980 - 2006, 31 presented with thrombocytosis. The majority (71%) had low risk features and a low incidence of spontaneous bleeding or thrombo-embolic events. Compared to a case-matched control group of MDS and MDS/MPD patients without thrombocytosis of similar ages and IPSS scores, patients with thrombocytosis had a slightly lower probability of progression to a higher grade of MDS (P = 0.03), equivalent risk of transformation to acute myeloid leukemia (AML), and a trend (P = 0.07) towards longer overall survival (median 35.4 months compared to 27.6 months for controls).
Kodali
Dhatri
D
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55417, USA.
Mesa
Hector
H
Rawal
Ajay
A
Cao
Qing
Q
Gupta
Pankaj
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000150:complications / Q000401:mortality; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000150:complications / Q000401:mortality; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000453:epidemiology / Q000209:etiology*